Effects of Functional Berry Extracts on Liver and Other Tissues of NAFLD Animal Models
Reference . | Extract intervention . | Animal model . | Intervention and animal groups . | Effects on liver of experimental groups that received berry extract vs NAFLDI group1 . | Effects on other tissues of experimental groups that received berry extract vs NAFLDI group1 . |
---|---|---|---|---|---|
Al Zarzour et al, 20171 | Phyllanthus niruri, MeOH-W extract |
|
|
|
|
Tavares et al, 20202 | Euterpe oleracea Mart. hydroalcoholic extract |
|
|
|
|
De Oliveira et al,20153 | Euterpe oleracea Mart. hydroalcoholic extract |
|
|
|
|
Morrison et al, 20154 | Vaccinium myrtillus L. extract |
|
|
| – |
Park et al, 20175 | Aronia melanocarpa ethanolic extract |
|
|
|
|
Park et al, 201936 | Water extract of mulberry and silk amino acids |
|
|
|
|
Xu et al, 201730 | Morus alba L. hydroalcoholic extract |
|
|
|
|
Ann et al, 201532 | Morus alba L. ethanolic extract |
|
|
|
|
Hu et al, 202033 | Morus alba L. methanolic extract |
|
|
| – |
Lee et al, 202034 | Morus alba fermented extract |
|
|
| ↓ BW |
Ma et al, 201835 | Morus alba ethanolic extract |
|
| Groups 4, 5: ↓ Srebf1 and Mlxipl Group 4: ↓ Fasn |
|
Park et al, 20199 | Rubus fruticosus ethanolic extract |
|
|
|
|
Peng et al, 20176 | Morus alba aqueous extract |
|
|
|
|
Song et al, 201631 | Morus nigra L. ethanolic extract |
|
|
|
|
Yang et al, 201837 | Morus alba ethanolic extract |
|
|
| ↓ TG, TC, LDL, AST, and ALT, ↑ HDL (serum) |
Fotschki et al, 202138 | Rubus idaeus L. acetone-water extract |
|
|
|
|
Li et al, 201439 | Rubus aleaefolius Poir extract |
|
| ↓ Fat accumulation, hepatocyte ballooning, scattered lobular inflammatory cell infiltration, and inflammatory foci, ↓ Acaca, Fasn, Cpt1a | ↓ TG, TC, LDL; ↑ HDL (serum) |
Nam et al, 201440 | Rubus coreanus |
|
| ↓ LW, TG, and TC, Nr1h3, Srebf1, Acaca, Cd36, Fasn, FASN, and HMGCR reductase activity; ↑CPT activity |
|
Zhao et al, 201341 | Rubus aleaefolius Poir. extract |
|
|
| Groups 4, 5: ↓ BW ↓ ALT, AST, GGT, ALP, TC, TG, and LDL serum levels |
Bae et al, 201742 | Lycium chinense aqueous extract |
|
|
| ↓ AST and ALT plasma levels |
Glisan et al, 201643 | Vaccinium macrocarpon acetone:water:acetic acid (80:19.9:0.1, v:v:v) extract |
|
| ↓ Degree of lipidosis and lipid droplets area, ↓ TNF-α, CCL2, and IL1b; ↓ Tlr4, NFKB, Tnfa, Il1b, Ucp2, Ptgs2, Ccr2, Ccl3, Nlrp3, Casp1, Ppara, Txnip | ↓ FFA, IL-1b, ALT plasma levels |
Huang et al, 201744 | Phyllantus emblica L. aqueous extract |
|
|
|
|
Tung et al, 201852 | Phyllanthus emblica L. reverse osmosis aqueous extract |
|
|
|
|
Xiao et al, 201845 | Lycium barbarum Lynn aqueous extract |
|
|
|
|
Pak et al,201223 | Vitis coignetiae Pulliat aqueous extract |
|
|
|
|
Al Zarzour et al, 201847 | Phyllanthus niruri methanolic extract |
|
|
|
|
Nanashima et al, 202050 | Ribes nigrum L. commercial extract |
|
|
|
|
Santos et al, 201748 | Vitis vinifera L. hydroalcoholic extract |
|
|
|
|
Charradi et al, 201451 | Vitis vinifera ethanolic extract |
|
|
| – |
De Bem et al, 201846 | Euterpe oleracea Mart. hydroalcoholic extract |
|
|
|
|
Freitas et al, 201649 | Euterpe edulis oil extract or defatted extract |
|
|
| Group 6: ↑ TC serum levels |
Reference . | Extract intervention . | Animal model . | Intervention and animal groups . | Effects on liver of experimental groups that received berry extract vs NAFLDI group1 . | Effects on other tissues of experimental groups that received berry extract vs NAFLDI group1 . |
---|---|---|---|---|---|
Al Zarzour et al, 20171 | Phyllanthus niruri, MeOH-W extract |
|
|
|
|
Tavares et al, 20202 | Euterpe oleracea Mart. hydroalcoholic extract |
|
|
|
|
De Oliveira et al,20153 | Euterpe oleracea Mart. hydroalcoholic extract |
|
|
|
|
Morrison et al, 20154 | Vaccinium myrtillus L. extract |
|
|
| – |
Park et al, 20175 | Aronia melanocarpa ethanolic extract |
|
|
|
|
Park et al, 201936 | Water extract of mulberry and silk amino acids |
|
|
|
|
Xu et al, 201730 | Morus alba L. hydroalcoholic extract |
|
|
|
|
Ann et al, 201532 | Morus alba L. ethanolic extract |
|
|
|
|
Hu et al, 202033 | Morus alba L. methanolic extract |
|
|
| – |
Lee et al, 202034 | Morus alba fermented extract |
|
|
| ↓ BW |
Ma et al, 201835 | Morus alba ethanolic extract |
|
| Groups 4, 5: ↓ Srebf1 and Mlxipl Group 4: ↓ Fasn |
|
Park et al, 20199 | Rubus fruticosus ethanolic extract |
|
|
|
|
Peng et al, 20176 | Morus alba aqueous extract |
|
|
|
|
Song et al, 201631 | Morus nigra L. ethanolic extract |
|
|
|
|
Yang et al, 201837 | Morus alba ethanolic extract |
|
|
| ↓ TG, TC, LDL, AST, and ALT, ↑ HDL (serum) |
Fotschki et al, 202138 | Rubus idaeus L. acetone-water extract |
|
|
|
|
Li et al, 201439 | Rubus aleaefolius Poir extract |
|
| ↓ Fat accumulation, hepatocyte ballooning, scattered lobular inflammatory cell infiltration, and inflammatory foci, ↓ Acaca, Fasn, Cpt1a | ↓ TG, TC, LDL; ↑ HDL (serum) |
Nam et al, 201440 | Rubus coreanus |
|
| ↓ LW, TG, and TC, Nr1h3, Srebf1, Acaca, Cd36, Fasn, FASN, and HMGCR reductase activity; ↑CPT activity |
|
Zhao et al, 201341 | Rubus aleaefolius Poir. extract |
|
|
| Groups 4, 5: ↓ BW ↓ ALT, AST, GGT, ALP, TC, TG, and LDL serum levels |
Bae et al, 201742 | Lycium chinense aqueous extract |
|
|
| ↓ AST and ALT plasma levels |
Glisan et al, 201643 | Vaccinium macrocarpon acetone:water:acetic acid (80:19.9:0.1, v:v:v) extract |
|
| ↓ Degree of lipidosis and lipid droplets area, ↓ TNF-α, CCL2, and IL1b; ↓ Tlr4, NFKB, Tnfa, Il1b, Ucp2, Ptgs2, Ccr2, Ccl3, Nlrp3, Casp1, Ppara, Txnip | ↓ FFA, IL-1b, ALT plasma levels |
Huang et al, 201744 | Phyllantus emblica L. aqueous extract |
|
|
|
|
Tung et al, 201852 | Phyllanthus emblica L. reverse osmosis aqueous extract |
|
|
|
|
Xiao et al, 201845 | Lycium barbarum Lynn aqueous extract |
|
|
|
|
Pak et al,201223 | Vitis coignetiae Pulliat aqueous extract |
|
|
|
|
Al Zarzour et al, 201847 | Phyllanthus niruri methanolic extract |
|
|
|
|
Nanashima et al, 202050 | Ribes nigrum L. commercial extract |
|
|
|
|
Santos et al, 201748 | Vitis vinifera L. hydroalcoholic extract |
|
|
|
|
Charradi et al, 201451 | Vitis vinifera ethanolic extract |
|
|
| – |
De Bem et al, 201846 | Euterpe oleracea Mart. hydroalcoholic extract |
|
|
|
|
Freitas et al, 201649 | Euterpe edulis oil extract or defatted extract |
|
|
| Group 6: ↑ TC serum levels |
Outcomes refer to groups with berry extract administration vs groups after NAFLD induction, unless otherwise specified.
Abbreviations: A/W, age/weight; AI, atherogenic index (AI); AUC ROC, area under the receiver operating characteristic curve; BE, berry extract; BW, body weight; CCB, cocoa butter; CEL, cellulose; CHOL, cholesterol; CO, corn oil; CS, corn starch; DW, distilled water; FA, fatty acid; FFA, free fatty acid; Glu, glucose; HFD, high-fat diet; IG, intragastric; Ins, insulin; IP, intraperitoneal; LFD, low-fat diet; LW, liver weight; M, animal model; MCD, methionine-choline–deficient diet; MeOH, methanol; mHFD, modified high-fat diet; NAFLDI, nonalcoholic fatty liver disease induction; ND, normal diet; OA, orotic acid; OAD, orotic acid diet; OG, oral gavage; OO, olive oil; SA, silk amino acid; SD, Sprague-Dawley rats; STZ, streptozotocin; SUC, sucrose; TG, triglyceride; TEAC, trolox equivalent antioxidant capacity; TP, treatment period; V, vehicle; W, water; WTD, Western-type diet.
Biomarker abbreviations (genes and proteins): ABCG5, ABCG8: ATP binding cassette subfamily G member 5 and 8; ACC or ACACA: acetyl-CoA carboxylase; AdipoR2: adiponectin Receptor 2; AGPAT: 1-acylglycerol-3-phosphate-O-acyltransferase enzyme; ALAT: alanine transaminase; ALP, alkaline phosphatase; ANGPTL4: angiopoietin-like 4 gene; Apo: apolipoprotein; aP2 or FABP4: fatty acid binding protein 4; ASAT: aspartate aminotransferase; ASC or PYCARD: apoptosis-associated speck-like protein containing a CARD; α-SMA or Acta2: α smooth muscle actin; AST: aspartate aminotransferase; Atg4b, Atg5, Atg7, Atg12: autophagy-related cysteine peptidase 4, 5, 7, and 12; Bax-1: apoptosis regulator BAX; Bcl-2: B-cell lymphoma 2; CAT: catalase; CASP1: Casparian strip membrane protein 1; CCR2: C-C chemokine receptor type 2; CCL2 or 3: C-C motif chemokine ligand 2 or 3 protein; CD11c or Itgax: integrin α-X; CD36: platelet glycoprotein 4; C/EBPα or Cebpa: CCAAT-enhancer-binding proteins; CK-18: cytokeratin 18; CYP7A1: cholesterol 7-α-monooxygenase; CYP2E1: cytochrome P450 2E1; CPT1: carnitine palmitoyltransferase; Col1a1: collagen type I α 1 chain; COX2 or Ptgs2: cyclooxygenase-2; Mlxipl; ChREBP: carbohydrate-responsive element-binding protein; CYP2E1: N-nitrosodimethyl-amine demethylase; ERK: extracellular-signal-regulated kinase; Fabp4: fatty acid-binding protein 4; FASN: fatty acid synthase enzyme; Fads2: acyl-CoA 6-desaturase; F4/80: rat anti–mouse F4/80 antibody; GSH: glutathione reductase; GSSG: glutathione disulfide; GST: glutathione S-transferase; GPx: glutathione peroxide; GRd: glutathione reductase; Gk or GYK: glycerol kinase; SLC2A2 or Glut 2: glucose transporter 2; 4-HNE: 4-hydroxynonenal; HMGCR: 3-hydroxy-3-methy-glutaril-CoA reductase enzyme; HO-1: heme oxygenase-1; ICAM-1: intercellular adhesion molecule; IκB-α or Nfkbia: nuclear factor of κ light polypeptide gene enhancer in B-cells inhibitor, α; IL-6: interleukin 6 cytokine featuring pleiotropic activity; IL-1β: interleukin -1 β pro-inflammatory cytokine produced by cells of the innate immune system; Nos2 or iNOS: inducible nitric oxide synthase; INSIG1: insulin induced gene 1; JNK: Jun N-terminal kinase; Klf2: Krüppel-like factor 2; LC3: microtubule-associated protein light chain 3; LPL: lipoprotein lipase; LXRa or Nr1h3: liver X receptor α; MDA: malondialdehyde; MPO: myeloperoxidase; miR-33a: microRNA 33a; NADPH: nicotinamide adenine dinucleotide phosphate; NAS: NAFLD Activity Score; NF-κB: nuclear factor κ B; NLRP3: NACHT, LRR, and PYD domains-containing protein 3; NLRP6: NOD‐like receptor family pyrin domain containing 6; Nrf2: nuclear factor erythroid 2-related factor 2; NOX4: NADPH oxidase 4; PPAR-γ: peroxisome proliferator-activated receptor γ; pAMPK: phosphorylated AMP-activated protein kinase; pAKT: phospho-AKT; p-ERK: extracellular signal-related kinase; p-IRS-1: phosphorylated insulin receptor substrate; PI3-1K: phosphatidylinositol 3-kinase 1; p-mTOR: phosphorylated serine/threonine-protein kinase mTOR; p-JNK: phosphorylated Jun N-terminal kinase; LKB1: serine/threonine protein kinase liver kinase B1; p-PI3K: phosphorylated phosphatidylinositol-3 kinase; PPARα: peroxisome proliferator-activated receptor α; ROS: reactive oxygen species; SCD-1: stearoyl-coenzyme A desaturase 1; SOD: superoxide dismutase; SLC10A2: ileal sodium/bile acid cotransporter; Smad2: Mothers Against Decantaplegic homolog 2; SREBP: sterol regulatory element-binding protein; Srebf1: sterol regulatory element binding transcription factor 1; TGF-β: transforming growth factor β; TXNIP: thioredoxin-interacting protein; TBARS: thiobarbituric acid reactive substances; TPL: protein TOPLESS; TNF-α: tumor necrosis factor α; Tlr4: Toll-like receptor 4; UCP2: mitochondrial uncoupling protein 2.
Effects of Functional Berry Extracts on Liver and Other Tissues of NAFLD Animal Models
Reference . | Extract intervention . | Animal model . | Intervention and animal groups . | Effects on liver of experimental groups that received berry extract vs NAFLDI group1 . | Effects on other tissues of experimental groups that received berry extract vs NAFLDI group1 . |
---|---|---|---|---|---|
Al Zarzour et al, 20171 | Phyllanthus niruri, MeOH-W extract |
|
|
|
|
Tavares et al, 20202 | Euterpe oleracea Mart. hydroalcoholic extract |
|
|
|
|
De Oliveira et al,20153 | Euterpe oleracea Mart. hydroalcoholic extract |
|
|
|
|
Morrison et al, 20154 | Vaccinium myrtillus L. extract |
|
|
| – |
Park et al, 20175 | Aronia melanocarpa ethanolic extract |
|
|
|
|
Park et al, 201936 | Water extract of mulberry and silk amino acids |
|
|
|
|
Xu et al, 201730 | Morus alba L. hydroalcoholic extract |
|
|
|
|
Ann et al, 201532 | Morus alba L. ethanolic extract |
|
|
|
|
Hu et al, 202033 | Morus alba L. methanolic extract |
|
|
| – |
Lee et al, 202034 | Morus alba fermented extract |
|
|
| ↓ BW |
Ma et al, 201835 | Morus alba ethanolic extract |
|
| Groups 4, 5: ↓ Srebf1 and Mlxipl Group 4: ↓ Fasn |
|
Park et al, 20199 | Rubus fruticosus ethanolic extract |
|
|
|
|
Peng et al, 20176 | Morus alba aqueous extract |
|
|
|
|
Song et al, 201631 | Morus nigra L. ethanolic extract |
|
|
|
|
Yang et al, 201837 | Morus alba ethanolic extract |
|
|
| ↓ TG, TC, LDL, AST, and ALT, ↑ HDL (serum) |
Fotschki et al, 202138 | Rubus idaeus L. acetone-water extract |
|
|
|
|
Li et al, 201439 | Rubus aleaefolius Poir extract |
|
| ↓ Fat accumulation, hepatocyte ballooning, scattered lobular inflammatory cell infiltration, and inflammatory foci, ↓ Acaca, Fasn, Cpt1a | ↓ TG, TC, LDL; ↑ HDL (serum) |
Nam et al, 201440 | Rubus coreanus |
|
| ↓ LW, TG, and TC, Nr1h3, Srebf1, Acaca, Cd36, Fasn, FASN, and HMGCR reductase activity; ↑CPT activity |
|
Zhao et al, 201341 | Rubus aleaefolius Poir. extract |
|
|
| Groups 4, 5: ↓ BW ↓ ALT, AST, GGT, ALP, TC, TG, and LDL serum levels |
Bae et al, 201742 | Lycium chinense aqueous extract |
|
|
| ↓ AST and ALT plasma levels |
Glisan et al, 201643 | Vaccinium macrocarpon acetone:water:acetic acid (80:19.9:0.1, v:v:v) extract |
|
| ↓ Degree of lipidosis and lipid droplets area, ↓ TNF-α, CCL2, and IL1b; ↓ Tlr4, NFKB, Tnfa, Il1b, Ucp2, Ptgs2, Ccr2, Ccl3, Nlrp3, Casp1, Ppara, Txnip | ↓ FFA, IL-1b, ALT plasma levels |
Huang et al, 201744 | Phyllantus emblica L. aqueous extract |
|
|
|
|
Tung et al, 201852 | Phyllanthus emblica L. reverse osmosis aqueous extract |
|
|
|
|
Xiao et al, 201845 | Lycium barbarum Lynn aqueous extract |
|
|
|
|
Pak et al,201223 | Vitis coignetiae Pulliat aqueous extract |
|
|
|
|
Al Zarzour et al, 201847 | Phyllanthus niruri methanolic extract |
|
|
|
|
Nanashima et al, 202050 | Ribes nigrum L. commercial extract |
|
|
|
|
Santos et al, 201748 | Vitis vinifera L. hydroalcoholic extract |
|
|
|
|
Charradi et al, 201451 | Vitis vinifera ethanolic extract |
|
|
| – |
De Bem et al, 201846 | Euterpe oleracea Mart. hydroalcoholic extract |
|
|
|
|
Freitas et al, 201649 | Euterpe edulis oil extract or defatted extract |
|
|
| Group 6: ↑ TC serum levels |
Reference . | Extract intervention . | Animal model . | Intervention and animal groups . | Effects on liver of experimental groups that received berry extract vs NAFLDI group1 . | Effects on other tissues of experimental groups that received berry extract vs NAFLDI group1 . |
---|---|---|---|---|---|
Al Zarzour et al, 20171 | Phyllanthus niruri, MeOH-W extract |
|
|
|
|
Tavares et al, 20202 | Euterpe oleracea Mart. hydroalcoholic extract |
|
|
|
|
De Oliveira et al,20153 | Euterpe oleracea Mart. hydroalcoholic extract |
|
|
|
|
Morrison et al, 20154 | Vaccinium myrtillus L. extract |
|
|
| – |
Park et al, 20175 | Aronia melanocarpa ethanolic extract |
|
|
|
|
Park et al, 201936 | Water extract of mulberry and silk amino acids |
|
|
|
|
Xu et al, 201730 | Morus alba L. hydroalcoholic extract |
|
|
|
|
Ann et al, 201532 | Morus alba L. ethanolic extract |
|
|
|
|
Hu et al, 202033 | Morus alba L. methanolic extract |
|
|
| – |
Lee et al, 202034 | Morus alba fermented extract |
|
|
| ↓ BW |
Ma et al, 201835 | Morus alba ethanolic extract |
|
| Groups 4, 5: ↓ Srebf1 and Mlxipl Group 4: ↓ Fasn |
|
Park et al, 20199 | Rubus fruticosus ethanolic extract |
|
|
|
|
Peng et al, 20176 | Morus alba aqueous extract |
|
|
|
|
Song et al, 201631 | Morus nigra L. ethanolic extract |
|
|
|
|
Yang et al, 201837 | Morus alba ethanolic extract |
|
|
| ↓ TG, TC, LDL, AST, and ALT, ↑ HDL (serum) |
Fotschki et al, 202138 | Rubus idaeus L. acetone-water extract |
|
|
|
|
Li et al, 201439 | Rubus aleaefolius Poir extract |
|
| ↓ Fat accumulation, hepatocyte ballooning, scattered lobular inflammatory cell infiltration, and inflammatory foci, ↓ Acaca, Fasn, Cpt1a | ↓ TG, TC, LDL; ↑ HDL (serum) |
Nam et al, 201440 | Rubus coreanus |
|
| ↓ LW, TG, and TC, Nr1h3, Srebf1, Acaca, Cd36, Fasn, FASN, and HMGCR reductase activity; ↑CPT activity |
|
Zhao et al, 201341 | Rubus aleaefolius Poir. extract |
|
|
| Groups 4, 5: ↓ BW ↓ ALT, AST, GGT, ALP, TC, TG, and LDL serum levels |
Bae et al, 201742 | Lycium chinense aqueous extract |
|
|
| ↓ AST and ALT plasma levels |
Glisan et al, 201643 | Vaccinium macrocarpon acetone:water:acetic acid (80:19.9:0.1, v:v:v) extract |
|
| ↓ Degree of lipidosis and lipid droplets area, ↓ TNF-α, CCL2, and IL1b; ↓ Tlr4, NFKB, Tnfa, Il1b, Ucp2, Ptgs2, Ccr2, Ccl3, Nlrp3, Casp1, Ppara, Txnip | ↓ FFA, IL-1b, ALT plasma levels |
Huang et al, 201744 | Phyllantus emblica L. aqueous extract |
|
|
|
|
Tung et al, 201852 | Phyllanthus emblica L. reverse osmosis aqueous extract |
|
|
|
|
Xiao et al, 201845 | Lycium barbarum Lynn aqueous extract |
|
|
|
|
Pak et al,201223 | Vitis coignetiae Pulliat aqueous extract |
|
|
|
|
Al Zarzour et al, 201847 | Phyllanthus niruri methanolic extract |
|
|
|
|
Nanashima et al, 202050 | Ribes nigrum L. commercial extract |
|
|
|
|
Santos et al, 201748 | Vitis vinifera L. hydroalcoholic extract |
|
|
|
|
Charradi et al, 201451 | Vitis vinifera ethanolic extract |
|
|
| – |
De Bem et al, 201846 | Euterpe oleracea Mart. hydroalcoholic extract |
|
|
|
|
Freitas et al, 201649 | Euterpe edulis oil extract or defatted extract |
|
|
| Group 6: ↑ TC serum levels |
Outcomes refer to groups with berry extract administration vs groups after NAFLD induction, unless otherwise specified.
Abbreviations: A/W, age/weight; AI, atherogenic index (AI); AUC ROC, area under the receiver operating characteristic curve; BE, berry extract; BW, body weight; CCB, cocoa butter; CEL, cellulose; CHOL, cholesterol; CO, corn oil; CS, corn starch; DW, distilled water; FA, fatty acid; FFA, free fatty acid; Glu, glucose; HFD, high-fat diet; IG, intragastric; Ins, insulin; IP, intraperitoneal; LFD, low-fat diet; LW, liver weight; M, animal model; MCD, methionine-choline–deficient diet; MeOH, methanol; mHFD, modified high-fat diet; NAFLDI, nonalcoholic fatty liver disease induction; ND, normal diet; OA, orotic acid; OAD, orotic acid diet; OG, oral gavage; OO, olive oil; SA, silk amino acid; SD, Sprague-Dawley rats; STZ, streptozotocin; SUC, sucrose; TG, triglyceride; TEAC, trolox equivalent antioxidant capacity; TP, treatment period; V, vehicle; W, water; WTD, Western-type diet.
Biomarker abbreviations (genes and proteins): ABCG5, ABCG8: ATP binding cassette subfamily G member 5 and 8; ACC or ACACA: acetyl-CoA carboxylase; AdipoR2: adiponectin Receptor 2; AGPAT: 1-acylglycerol-3-phosphate-O-acyltransferase enzyme; ALAT: alanine transaminase; ALP, alkaline phosphatase; ANGPTL4: angiopoietin-like 4 gene; Apo: apolipoprotein; aP2 or FABP4: fatty acid binding protein 4; ASAT: aspartate aminotransferase; ASC or PYCARD: apoptosis-associated speck-like protein containing a CARD; α-SMA or Acta2: α smooth muscle actin; AST: aspartate aminotransferase; Atg4b, Atg5, Atg7, Atg12: autophagy-related cysteine peptidase 4, 5, 7, and 12; Bax-1: apoptosis regulator BAX; Bcl-2: B-cell lymphoma 2; CAT: catalase; CASP1: Casparian strip membrane protein 1; CCR2: C-C chemokine receptor type 2; CCL2 or 3: C-C motif chemokine ligand 2 or 3 protein; CD11c or Itgax: integrin α-X; CD36: platelet glycoprotein 4; C/EBPα or Cebpa: CCAAT-enhancer-binding proteins; CK-18: cytokeratin 18; CYP7A1: cholesterol 7-α-monooxygenase; CYP2E1: cytochrome P450 2E1; CPT1: carnitine palmitoyltransferase; Col1a1: collagen type I α 1 chain; COX2 or Ptgs2: cyclooxygenase-2; Mlxipl; ChREBP: carbohydrate-responsive element-binding protein; CYP2E1: N-nitrosodimethyl-amine demethylase; ERK: extracellular-signal-regulated kinase; Fabp4: fatty acid-binding protein 4; FASN: fatty acid synthase enzyme; Fads2: acyl-CoA 6-desaturase; F4/80: rat anti–mouse F4/80 antibody; GSH: glutathione reductase; GSSG: glutathione disulfide; GST: glutathione S-transferase; GPx: glutathione peroxide; GRd: glutathione reductase; Gk or GYK: glycerol kinase; SLC2A2 or Glut 2: glucose transporter 2; 4-HNE: 4-hydroxynonenal; HMGCR: 3-hydroxy-3-methy-glutaril-CoA reductase enzyme; HO-1: heme oxygenase-1; ICAM-1: intercellular adhesion molecule; IκB-α or Nfkbia: nuclear factor of κ light polypeptide gene enhancer in B-cells inhibitor, α; IL-6: interleukin 6 cytokine featuring pleiotropic activity; IL-1β: interleukin -1 β pro-inflammatory cytokine produced by cells of the innate immune system; Nos2 or iNOS: inducible nitric oxide synthase; INSIG1: insulin induced gene 1; JNK: Jun N-terminal kinase; Klf2: Krüppel-like factor 2; LC3: microtubule-associated protein light chain 3; LPL: lipoprotein lipase; LXRa or Nr1h3: liver X receptor α; MDA: malondialdehyde; MPO: myeloperoxidase; miR-33a: microRNA 33a; NADPH: nicotinamide adenine dinucleotide phosphate; NAS: NAFLD Activity Score; NF-κB: nuclear factor κ B; NLRP3: NACHT, LRR, and PYD domains-containing protein 3; NLRP6: NOD‐like receptor family pyrin domain containing 6; Nrf2: nuclear factor erythroid 2-related factor 2; NOX4: NADPH oxidase 4; PPAR-γ: peroxisome proliferator-activated receptor γ; pAMPK: phosphorylated AMP-activated protein kinase; pAKT: phospho-AKT; p-ERK: extracellular signal-related kinase; p-IRS-1: phosphorylated insulin receptor substrate; PI3-1K: phosphatidylinositol 3-kinase 1; p-mTOR: phosphorylated serine/threonine-protein kinase mTOR; p-JNK: phosphorylated Jun N-terminal kinase; LKB1: serine/threonine protein kinase liver kinase B1; p-PI3K: phosphorylated phosphatidylinositol-3 kinase; PPARα: peroxisome proliferator-activated receptor α; ROS: reactive oxygen species; SCD-1: stearoyl-coenzyme A desaturase 1; SOD: superoxide dismutase; SLC10A2: ileal sodium/bile acid cotransporter; Smad2: Mothers Against Decantaplegic homolog 2; SREBP: sterol regulatory element-binding protein; Srebf1: sterol regulatory element binding transcription factor 1; TGF-β: transforming growth factor β; TXNIP: thioredoxin-interacting protein; TBARS: thiobarbituric acid reactive substances; TPL: protein TOPLESS; TNF-α: tumor necrosis factor α; Tlr4: Toll-like receptor 4; UCP2: mitochondrial uncoupling protein 2.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.